Agios Pharmaceuticals, Inc. — FY2015 Form 10-K
Reporting period: Fiscal year ended December 31, 2015; selected quarterly data includes the three months ended December 31, 2015. Agios is a clinical-stage biopharmaceutical company developing small-molecule therapies for cancer and rare genetic metabolic disorders. Its lead programs were AG-221 and AG-120 (mutant IDH2/IDH1), AG-881 (pan-IDH), and AG-348 (pyruvate kinase deficiency). The company had no product-sales revenue.
Financial results and liquidity
| Metric | FY2015 | FY2014 |
|---|---|---|
| Collaboration revenue, primarily from Celgene | $59.1 million | $65.4 million |
| Research and development expense, net | $141.8 million | $100.4 million |
| General and administrative expense | $36.0 million | $19.1 million |
| Operating loss | $118.7 million | $54.1 million |
| Net loss | $117.7 million | $53.5 million |
| Net loss per share, basic and diluted | $3.15 | $1.59 |
| Net cash used in operating activities | $76.9 million | $59.4 million |
Revenue declined 9.5%, while R&D expense rose 41.3% and G&A expense rose 88.2%; net loss more than doubled. The company attributed higher costs mainly to expanded clinical activity, staffing and facilities. Revenue is collaboration-based, not recurring product sales; FY2015 included $27.8 million recognized upon delivery of the AG-120 and AG-881 licenses. Celgene cost reimbursements of $25.2 million were recorded as a reduction of R&D expense.
Fourth quarter: Revenue was $6.2 million, versus $14.6 million in Q4 2014. Operating loss was $40.9 million and net loss was $40.6 million, versus losses of $26.7 million in each measure in Q4 2014. Q4 2015 net loss per share was $1.08.
At year-end, cash, cash equivalents and marketable securities totaled $375.9 million, down from $467.4 million. Total assets were $420.1 million; total liabilities were $74.9 million; stockholders’ equity was $345.1 million. Current assets were $337.3 million and current liabilities $52.9 million. The filing reports no off-balance-sheet arrangements and does not identify outstanding borrowings or a material debt balance. Operating cash outflow increased year over year; investing activities provided $128.3 million, primarily from maturities and sales of marketable securities, while financing activities provided $6.4 million. Capital expenditures were $20.2 million.
Management expected year-end resources, anticipated interest income and expected Celgene reimbursements to fund operations and capital needs until at least late 2017. This is an estimate dependent on clinical spending, collaboration activity and other assumptions, not a guarantee. No product gross margin or operating margin is meaningful because Agios had no product sales and continued to incur operating losses.
Business developments and material changes
- AG-221 advanced into the phase 3 IDHENTIFY trial in older patients with IDH2-mutant AML; Celgene leads and funds its development. Agios reported 79 objective responses among 209 response-evaluable AML patients in an ongoing early-stage trial, including 37 complete remissions. These were investigator-assessed, non-pivotal results.
- AG-120 remained in phase 1 trials. Agios reported 27 objective responses among 78 response-evaluable patients with IDH1-mutant hematologic malignancies, including 12 complete remissions. In solid tumors, reported activity included stable disease and a partial response in selected small cohorts.
- AG-881 entered phase 1 development in 2015 for solid tumors and hematologic malignancies, including disease progressing after prior IDH-inhibitor treatment. Agios and Celgene share worldwide development costs and profits under a separate collaboration.
- AG-348 entered the phase 2 DRIVE PK trial in adults with pyruvate kinase deficiency. Earlier healthy-volunteer studies showed pharmacodynamic changes in ATP and 2,3-DPG; patient efficacy remained to be established.
- Celgene paid $20 million in 2015 to extend the cancer-metabolism discovery period through April 2016 and made a $10 million upfront payment under the AG-881 agreements. A $25 million AG-221 clinical milestone was earned and received in January 2016, after year-end, and is not FY2015 cash or revenue.
Outlook, risks and unusual items
Management expected R&D and operating losses to increase as trials expanded and programs progressed. It anticipated no near-term product-sales revenue and stated that additional funding may be needed; available financing could dilute shareholders or require surrendering program rights. Agios had never obtained marketing approval for a product.
- Key uncertainties include whether clinical results will be confirmed in larger or later-stage trials, safety and tolerability, patient enrollment, regulatory approval and commercial adoption. Early response data do not establish efficacy or approval prospects.
- The business depends substantially on Celgene for collaboration revenue, cost reimbursement and development of certain programs. Celgene can terminate agreements for convenience with notice; the 2010 discovery phase was scheduled to end in April 2016.
- Agios relied on third-party manufacturers and research organizations, had no long-term supply arrangements or redundant bulk-drug supply, and identified manufacturing and trial execution as risks.
- Other material risks include intellectual-property challenges, companion-diagnostic development and approval, competition, reimbursement and pricing pressures, and the need for future capital. The company disclosed no material ongoing legal proceedings; prior University of Pennsylvania-related lawsuits were settled in 2012.
- FY2015 collaboration revenue and expenses reflect complex Celgene agreement accounting, license deliveries and cost reimbursements. Stock-based compensation rose to $32.0 million from $11.5 million. The filing also reports an accumulated deficit of $284.7 million in the audited balance sheet and selected financial data, but one MD&A passage states $248.7 million; this appears inconsistent and should be checked against the audited statements.
Most important facts for investors to verify
- Reconcile the accumulated-deficit inconsistency and review the audited financial statements and Celgene collaboration revenue-recognition disclosures.
- Track cash burn against the stated late-2017 runway, including the effect of trial expansion, cost-sharing and reimbursements, and post-year-end milestone receipts.
- Verify subsequent clinical-trial data, response durability and safety for AG-221 and AG-120, and patient results for AG-348; distinguish early-stage findings from pivotal evidence.
- Confirm the status and terms of the Celgene discovery phase after April 2016, program responsibilities, and any milestones, reimbursements or termination decisions.
- Assess dilution and future financing needs, as well as manufacturing capacity, supply redundancy and companion-diagnostic readiness.